Reapplix Seals In More Funding For Diabetic Foot Ulcer Patch
Executive Summary
Reapplix, an emerging autologous cell-based wound therapy specialist, has secured additional funding that will take the company through the next year before it gets “market-ready” to launch its diabetic foot ulcer treatment in the US and EU.
You may also be interested in...
Reapplix gets US FDA green light for autologous cell-based wound therapy
The increasingly heated regenerative medicine space is to welcome another new entrant in the US market, following FDA clearance of Reapplix’s 3C Patch System.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.